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Abstract: A new bifunctional macrocyclic chelator featuring a conjugatable alkynyl-naphthalimide
fluorophore pendant group has been prepared and its Gd(III) complex coupled to a cell-penetrating
lipidated azido-Tat peptide derivative using Cu(I)-catalysed “click” chemistry. The resulting
fluorescent conjugate is able to enter CAL-33 tongue squamous carcinoma cells, as revealed by
confocal microscopy, producing a very modest anti-proliferative effect (IC50 = 93 µM). Due to the
photo-reactivity of the naphthalimide moiety, however, the conjugate’s cytotoxicity is significantly
enhanced (IC50 = 16 µM) upon brief low-power UV-A irradiation.
Keywords: cell-penetrating peptide; fluorescence; gadolinium complex; photo-cytotoxicity; theranostic
1. Introduction
There continues to be much interest in the development of molecular imaging agents, including
ones that can be detected by more than one imaging modality (“multi-modal imaging agents”) [1–5].
This is particularly so within the field of oncology, where imaging agents are used extensively
for the screening, diagnosis, staging, planning of treatment, post-treatment assessment and
surveillance of cancer [6,7]. Another area that has seen rapid growth over the last decade is the
development of agents that can be used for both imaging and therapy (“theranostics”), allowing
for image-guided drug delivery, in vivo detection of drug release/activation, and/or monitoring of
patient’s response to therapy [8–10]. Designs range from small molecules and (bio)conjugates [11]
through to multi-functional nanoparticulate systems [12,13].
The most advanced theranostic designs are engineered to be stimuli-responsive, with activation
of therapeutic activity/drug release occurring in response to endogenous triggers (e.g., pH
change, hypoxia, elevated enzyme activity) or external stimuli (e.g., heat, light). This allows for
controlled dosing and/or reduced exposure of non-diseased cells/tissue to cytotoxic species [14,15].
The development of photo-responsive systems, in particular, has received considerable attention,
since light, as a stimulus, is generally non-invasive and can be readily manipulated, enabling
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drug activation/release to be controlled both spatially and temporally with extreme precision.
Photo-responsiveness is often achieved by loading bioactive cargo into carrier (nano)materials
that are amenable to dissociation/structural change upon exposure to light [16–18]. Alternatively,
light-activated pro-drugs may be employed in the construction of photo-responsive theranostic designs.
These include photo-sensitisers, which generate cytotoxic singlet oxygen (1O2) in response to light and
form the basis of photo-dynamic therapy (PDT) [19–21], and photo-activated chemotherapeutic (PACT)
agents, which induce cell death through mechanisms such as light-mediated ligand ejection, DNA
crosslinking and uncaging [22–27]. As an added benefit, many PDT and PACT agents are luminescent,
providing a ready means of detection [28–30].
The development of increasingly elaborate and sophisticated multi-modal imaging agent and
theranostic designs, including photo-responsive ones, has been aided by the advent of “bio-orthogonal”
chemistries, such as the Cu(I)-catalysed azide-alkyne cycloaddition reaction (“click reaction”) [31,32]
and its Cu-free variant—strain-promoted azide-alkyne cycloaddition (SPAAC) [33,34]. These allow
for the late-stage introduction of moieties into highly functionalised molecules (small molecules,
peptides, proteins) [35–38] and nanoparticles [39–41], as well as the controlled stepwise elaboration of
hetero-multifunctional scaffolds [42–44], without the need for complex protection group strategies.
The widespread adoption of bio-orthogonal labelling technologies in the biological and biomedical
sciences has also seen an expanding toolbox of “clickable” compounds (fluorophores, cross-linkers,
macrocyclic chelators, etc.) become available to researchers interested in multi-functional imaging and
therapeutic agents. Indeed, many such “building blocks” are now commercially available.
We have a particular interest in the development of metal complex-based agents for imaging
and therapy, including photo-cytotoxic complexes for potential application as new PDT and PACT
agents [45–52]. During the course of our work, a number of “clickable” metal complexes/chelators
have been developed and employed in the synthesis of peptide conjugates with tumour-targetting,
cell-penetrating and/or organelle-specific localising properties [53–56]. Additionally, we have
incorporated alkyne-bearing metal complexes into proteins via click conjugation to unnatural amino
acids to facilitate protein structural investigations [57–59]. Many other research groups have likewise
reported alkyne- and azide-bearing metal complexes/chelators for a range of biological and biomedical
applications [60–64].
As part of an effort to generate new photo-activated theranostics and multi-modal imaging agents,
we have now developed a new macrocyclic gadolinium(III) complex of a 1,4,7,10-tetraazacyclodocane-
1,4,7,10-tetraacetic acid (DOTA) derivative featuring a conjugatable alkynyl-napthalimide pendant.
Naphthalimide derivatives are widely employed as fluorescent dyes and are known to be
photo-reactive [65–71], while Gd(III)-DOTA-type complexes are well-established MRI contrast
agents [72–74]. To demonstrate its utility, the complex has been conjugated to a “model” peptide—a
lipidated, azide-bearing derivative of the cell-penetrating “Tat” peptide, derived from the HIV-1
“Trans-Activator of Transcription” protein [75]. We show that the “clicked” naphthalimide moiety can
be used for fluorescence tracking and results in a photo-cytotoxic effect when cellular entry of the
complex is facilitated by conjugation to the Tat peptide.
2. Results and Discussion
2.1. Synthesis of Ligand and Gd(III) Complexes
The synthesis of the ligand, L, commenced with a condensation reaction between
commercially-available 4-bromo-1,8-naphthalic anhydride and N-Boc-1,2-ethylenediamine, followed
by a Sonogashira reaction of the product (1) with trimethylsilyl (TMS) acetylene to install a
TMS-protected alkyne group in place of the bromo substituent (Scheme 1). Following Boc-deprotection
of 2 with trifluoroacetic acid (TFA), the exposed amine of 3 was reacted with bromoacetyl
bromide to produce the bromoacetamide derivative, 4. Compound 4 was subsequently coupled
to tert-butyl-protected 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (tBu3DO3A) [76]. Lastly, the
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TMS and tBu groups were removed using KF and TFA, respectively, to yield L, which was purified by
preparative HPLC.
The Gd(III) complex, Gd-L, was prepared by heating a neutral (pH 6.5–7.5) aqueous solution
of the ligand with two equiv. of gadolinium(III) acetate for 2 h, after which time LC-MS analysis
indicated near-quantitative complexation. Preparative HPLC was then used to purify the complex to
>95% purity.
As an initial test, Gd-L was conjugated to 3-azido-1-propanol as a model azide in aqueous solution.
CuSO4 (0.1 equiv.) was utilised as the copper source, sodium ascorbate (1 equiv.) as the reducing agent
and tris(3-hydroxypropyl-triazolylmethyl)amine (THTPA) (0.2 equiv.) as a Cu(I)-stabilising ligand [77,78].
After stirring overnight, conversion to the clicked product was near-quantitative according to LC-MS
analysis. The complex was again isolated in >95% purity following preparative HPLC.
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Scheme 1. Synthesis of ligand and Gd(III) complexes. (i) DMF, 80 ˝C, overnight (O/N), 91%;
(ii) TMS acetylene, Pd(PPh3)2Cl2, CuI, Et3N, THF, N2 atmosphere, RT, 3 h, 48%; (iii) TFA, DCM,
RT, 4 h, 96%; (iv) bromoacetyl bromide, Na2CO3, acetone, RT, 3 h, 59%; (v) tBu3DO3A.HBr, DIPEA,
ACN, reflux, O/N, 81%; (vi) (a) KF, H2O/ACN, RT, 2 h; (b) TFA, DCM, RT, O/N, 71% (over two
steps); (vii) Gd(OAc)3, ater ACN, 70 ˝C, 2 h, quant. (53% isolate ); (viii) 3-azido-1-propanol, CuSO4,
sodium ascorbate, THPTA, water/ACN, pH 7, RT, O/N, quant. (47% isolated).
2.2. Photo-Physical Properties of Complexes
The spectral properties of the two Gd(III) complexes were measured in aqueous solution buffered
at pH 7.4 with 100 mM HEPES. Table 1 summarises the data, while absorbance and fluorescence
emission spectra of the complexes are shown in Figure 1.
Click conjugation of the Gd-L complex is associated with a slight bathochromic shift (6 nm) in the
absorbance band arising from *pi-pi* transitions within the naphthalimide group. A much larger shift
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(54 nm) is observed for the fluorescence emission band and the fluorescence quantum yield is increased
by ca. 70%. These findings are in accordance with those reported for a simple N-ethyl naphthalimide
derivative bearing an alkyne at the 8-position [79].
Table 1. Photo-physical data for Gd(III) complexes measured in 100 mM HEPES, pH 7.4 (298 K).
Complex Absorption λmax(ε (M´1cm´1)) Emission λmax Φ
a (%) Brightness (ε ˆ Φ/1000(M´1cm´1))
Gd-L 356 (22,500) 417 35% 7.9
“Clicked” Gd-L 362 (19,200) 471 59% 11.3
a Quantum yield measured relative to quinine sulphate [80].
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Figure 1. Absorbance and fluorescence emission spectra of Gd(III) complexes (5 µM) in 100 mM HEPES,
pH 7.4 (298 K). Dot-dashed line: absorbance of Gd-L, dotted line: emission of Gd-L excited at 356 nm,
dashed line: absorbance of “clicked” Gd-L, solid line: emission of “clicked” Gd-L excited at 362 nm.
2.3. Conjugation of Complex to Lipidated Tat Peptide
To demonstrate its utility, the Gd-L complex was ligated to a derivative of the cell-penetrating Tat
peptide featuring a myristic acid tail at its N-terminus (to aid with cellular uptake) and an internal
azido-L-lysine residue (Figure 2). We have previously attached a luminescent rhenium(I) complex
to this lipidated peptide and visualised uptake of the resulting conjugate into cells via fluorescence
microscopy [55]. Stirring the peptide with Gd-L in the presence of CuSO4, sodium ascorbate and
THPTA at room temperature overnight led to essentially quantitative conversion, as judged by LC-MS
analysis. The product was isolated in 90% purity following preparative HPLC.
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Figure 2. Structure of Gd-L-bearing myristylated Tat peptide conjugate.
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2.4. (Photo-)cytotoxicity of Complexes and Conjugate
The cytotoxic properties of Gd-L, “clicked” Gd-L and the Gd-L-Tat peptide conjugate were
assessed on CAL-33 tongue squamous carcinoma cells, either in the dark or combined with short
exposure to a low-power dose of UV-A radiation (350 nm, 2.58 J¨ cm´2, 10 min). As the results in Table 2
indicate, the Gd-L and “clicked” Gd-L complexes exerted essentially no cytotoxic effect under either of
these conditions, with measured IC50 values >100 µM in all cases. The Tat conjugate also produced
only a very modest anti-proliferative effect when incubated with cells in the dark (IC50 « 93 µM).
However, a six-fold enhancement in cytotoxicity (IC50 « 16 µM) was observed when the conjugate was
exposed to UV-A radiation (see also Figure 3). These results reflect, first of all, that the myristylated Tat
peptide aids considerably with cellular uptake [55,81]. Secondly, the observed photo-cytotoxicity of
the conjugate is consistent with previous reports of the photo-reactivity of naphthalimide derivatives
towards biological molecules, including proteins and nucleic acids [65–71].
Table 2. Anti-proliferative effects of the Gd(III) complexes and Tat peptide conjugate on CAL-33 cancer
cells in the dark and upon light irradiation at 350 nm for 10 min (2.58 J¨ cm´2).
Compound IC50 (Dark) a (µM) IC50 (UV-A) a (µM) PI b (x-Fold)
Gd-L >100 >100 n.a.
“clicked” Gd-L >100 >100 n.a.
Gd-L-Tat conjugate 93 ˘ 3 16 ˘ 6 5.8
a expressed as mean˘ standard error of independent experiments; b PI = photo-toxic index = IC50 (UV-A)/IC50
(dark). n.a. = not applicable.
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Figure 3. Dose-response curves for the anti-proliferative effect of Gd-L-Tat peptide conjugate on
CAL-33 cells in the dark (black line) and upon UV-A irradiation (at 350 nm for 10 min, 2.58 J¨ cm´2;
grey line).
2.5. Cellular Uptake of Complexes and Conjugates
The ability of the two Gd(III) complexes and the Tat conjugate to enter CAL-33 cells was assessed
using confocal fluorescence microscopy (Figure 4). Although the optimal excitation and emission
wavelengths for the naphthalimide fluorophore are 356 and 417 nm for Gd-L and 362 and 471 nm
for “clicked” Gd-L, respectively (Table 1), the compounds could also be reliably detected using the
microscope’s “hybrid 1 red wavelength” channel (excitation: 405 nm; emission: 600´800 nm) because
of the brightness of the naphthalimide fluorophore, combined with the broadness of its absorption
and emission peaks. For cells incubated with “clicked” Gd-L, only extremely weak fluorescence
was observed (panels 2b and 3b), while cells treated with Gd-L were essentially non-fluorescent
(panels 2c and 3c), indicating that these complexes are not able to enter CAL-33 cells. In contrast, for
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cells incubated with the Gd-L-Tat peptide conjugate there was clear evidence of uptake and localisation
within the cytoplasmic regions of the cells (panel 3d). This is consistent with the results of previous
studies, which have shown that myristylated Tat is an effective cell-penetrating agent [55,81]. The
experiments were performed at 100 µM, a concentration that resulted in a clear Gd-L-Tat signal. At
this dose, it was possible to observe the early stages of induced cellular stress, in good agreement with
the cytotoxicity investigation. It is worthwhile noting that, besides cytosolic uptake, Gd-L-Tat also
displayed some punctate accumulation in regions ascribable to the cell nucleoli (panels 2d and 3d).
Overall, the confocal microscopy results help to rationalise the cytotoxicity data: the conjugate is the
only compound that exerts a cytotoxic effect because it is the only compound to enter the CAL-33 cells.
Molecules 2016, 21, 194 6 of 15 
 
uptake and localisation within the cytoplasmic regions of the cells (panel 3d). This is consistent with 
the results of previous studies, which have shown that myristylated Tat is an effective 
cell-penetrating agent [55,81]. The experiments were performed at 100 µM, a concentration that 
resulted in a clear Gd-L-Tat signal. At this dose, it was possible to observe the early stages of 
induced cellular stress, in good agreement with the cytotoxicity investigation. It is worthwhile 
noting that, besides cytosolic uptake, Gd-L-Tat also displayed some punctate accumulation in 
regions ascribable to the cell nucleoli (panels 2d and 3d). Overall, the confocal microscopy results 
help to rationalise the cytotoxicity data: the conjugate is the only compound that exerts a cytotoxic 
effect because it is the only compound to enter the CAL-33 cells. 
 
Figure 4. Confocal fluorescence microscopic images of CAL-33 cells incubated with Gd(III) 
complexes or conjugate for 4 h: (1a) DIC (differential interference contrast) image of the untreated 
Cal-33 cells; (2a) visualisation of background fluorescence in untreated CAL-33 cells using the 
excitation/emission wavelength settings (hybrid 1 channel) employed for detection of the Gd(III) 
compounds; (3a) merged image of the DIC and hybrid 1 channel images of untreated cells; (1b) DIC 
image of the CAL-33 cells treated with 100 μM of “clicked” Gd-L; (2b) visualisation of “clicked” 
Gd-L in cells; (3b) merged image of the DIC and hybrid 1 channel images of cells treated with 
“clicked” Gd-L; (1c) DIC image of the CAL-33 cells treated with 100 μM of Gd-L; (2c) visualisation of 
Gd-L in cells; (3c) merged image of the DIC and hybrid 1 channel images of cells treated with Gd-L; 
(1d) DIC image of the CAL-33 cells treated with 100 μM of Gd-L-Tat peptide conjugate; (2d) 
visualisation of Gd-L-Tat peptide conjugate in cells; (3d) merged image of the DIC and hybrid 1 
channel images of cells treated with Gd-L-Tat peptide conjugate. The scale bars represent 20 μm. 
Figure 4. Confocal fluorescence microscopic images of CAL-33 cells incubated with Gd(III) complexes
or conjugate for 4 h: (1a) DIC (differential interference contrast) image of the untreated Cal-33 cells;
(2a) visualisation of background fluorescence in untreated CAL-33 cells using the excitation/emission
wavelength settings (hybrid 1 channel) employed for detection of the Gd(III) compounds; (3a) merged
image of the DIC and hybrid 1 channel images of untreated cells; (1b) DIC image of the CAL-33 cells
treated with 100 µM of “clicked” Gd-L; (2b) visualisation of “clicked” Gd-L in cells; (3b) merged image
of the DIC and hybrid 1 channel images of cells treated with “clicked” Gd-L; (1c) DIC image of the
CAL-33 cells treated with 100 µM of Gd-L; (2c) visualisation of Gd-L in cells; (3c) merged image of
the DIC and hybrid 1 channel images of cells treated with Gd-L; (1d) DIC image of the CAL-33 cells
treated with 100 µM of Gd-L-Tat peptide conjugate; (2d) visualisation of Gd-L-Tat peptide conjugate in
cells; (3d) merged image of the DIC and hybrid 1 channel images of cells treated with Gd-L-Tat peptide
conjugate. The scale bars represent 20 µm.
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3. Experimental Section
3.1. Materials and Methods
All chemicals were purchased from Sigma-Aldrich Pty (St. Louis, MO, USA), Matrix Scientific
(Columbia, SC, USA), or Merck Group Ltd (Darmstadt, Germany) and used without purification.
1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid (tBu3DO3A.HBr) [76] and tris(3-hydroxypropyl-
triazolylmethyl)amine (THTPA) [77,78], were synthesised as per reported literature procedures. All
solvents were reagent, analytical or HPLC grade.
Flash chromatography was carried out using Merck 38 Silica gel 60, 230–400 mesh ASTM. Thin
layer chromatography (TLC) was performed on Merck Silica Gel 60 F254 plates. TLC plates were
visualised using a UV lamp at 254 nm or through the use of KMnO4 or ninhydrin staining agent.
Elemental analyses were performed by the Campbell Microanalytical Laboratory, Otago,
New Zealand.
1H and 13C nuclear magnetic resonance (NMR) spectra were recorded using an Avance III
Nanobay 400 MHz Bruker spectrometer (Billerica, MA, USA) coupled to the BACS 60 automatic sample
changer at 400.13 MHz and 100.61 MHz, respectively. Data acquisition and processing was managed
using Topspin software package version 3. Additional processing was handled with MestReNova
software (PC). Chemical shifts (δ) were measured in parts per million, referenced to an internal
standard of residual solvent. Spectroscopic data are given using the following abbreviations: s, singlet;
d, doublet; dd, doublet of doublets; ddd, doublet of doublet of doublets; dt, doublet of triplets; t, triplet;
m, multiplet; J, coupling constant.
Analytical high-performance liquid chromatography (HPLC) was carried out on an Agilent 1260
series modular HPLC (Santa Clara, CA, USA) equipped with the following modules: G1312B binary
pump, G1316A thermostated column compartment equipped with an Agilent Eclipse Plus C18 3.5 µm,
4.6 ˆ 100 mm column and a G1312B diode array detector. The following elution protocol was used:
0–10 min, gradient from 5% solvent B/95% solvent A to 100% solvent B (solvent A = 99.9% H2O,
0.1% TFA, and solvent B = 99.9% acetonitrile (ACN), 0.1% TFA, except in the case of the analysis of Gd
complexes, where solvent A = 99.9% H2O, 0.1% formic acid, and solvent B = 99.9% ACN, 0.1% formic
acid); flow rate = 1 mL¨min´1.
Preparative HPLC purification was carried out on an Agilent 1260 modular Prep HPLC equipped
with the following modules: G1361A prep pump, G2260A prep automatic liquid sampler, G1364B
fraction collector, G1315D diode array detector, and a Luna C8 5 µm, 100 Å AXIA, 250 ˆ 21.2 mm
column. The following elution protocol was used: 0–5 min, 100% solvent C; 5–30 min, gradient
from 100% solvent A to 20% solvent C/80% solvent D (solvent C = 99.9% H2O, 0.1% formic acid;
solvent D = 99.9% ACN, 0.1% formic acid); flow rate = 20 mL¨min´1.
High-resolution mass spectrometric (HRMS) analyses were performed on a Waters LCT TOF
LC-MS mass spectrometer (Milford, MA, USA) coupled to a 2795 Alliance Separations module. All
data were acquired and mass corrected via a dual-spray Leucine Enkephaline reference sample. Mass
spectra were generated by averaging the scans across each peak and background subtracted of the
TIC. Acquisition and analysis were performed using the MassLynx software version 4.1. The mass
spectrometer conditions were as follows: electrospray ionisation (ESI) mode, desolvation gas flow
of 550 L¨h´1, desolvation temperature of 250 ˝C, source temperature of 110 ˝C, capillary voltage of
2400 V, sample cone voltage of 60 V, scan range acquired between 100–1500 m/z, one sec scan times
and internal reference ions for positive ion mode (Leucine Enkephaline) of 556.2771.
Liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 6100 Series
Single Quad LC-MS coupled to an Agilent 1200 Series HPLC with the following mass spectrometer
conditions: multimode-ESI mode, 300 ˝C drying gas temperature, 200 ˝C vaporising temperature,
capillary voltage of 2000 V (positive), capillary voltage of 4000 V (negative), scan range between
100–1000 m/z with an 0.1 s step size and a 10 min acquisition time.
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Analysis of the peptide conjugates was performed on a Shimadzu modular LC-MS system
(Kyoto, Japan) equipped with the following modules: LC-20AD liquid chromatograph system,
SPD-M20A diode array detector, CTO-20A column oven equipped with a Luna 3 micron C8(2) 3 µm,
100 Å, 100 ˆ 2.0 mm column and a LC-MS-2020 system, operating in positive mode with an m/z scan
range of 200–2000.
Absorbance spectra were recorded on a Varian Cary 50 Bio UV-Vis spectrophotometer (Palo Alto,
CA, USA) using a 1 cm-path length quartz cuvette. Fluorescence emission spectra were acquired using
a Varian Cary Eclipse fluorescence spectrophotometer using a 1 cm-path length quartz cuvette.
3.2. Synthetic Procedures
3.2.1. tert-Butyl 2-(6-bromo-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethylcarbamate (1)
4-Bromo-1,8-napthalic anhydride (3.00 g, 10.8 mmol) and N-(tert-butoxycarbonyl)-1,
2-ethylenediamine (1.91 g, 11.9 mmol) were dissolved in DMF (30 mL) and stirred at 80 ˝C overnight
(O/N). The solution was then allowed to cool to room temperature (RT), before being poured into
ice-cold water to produce a yellow precipitate, which was collected via vacuum filtration, washed
several times with cold H2O and dried in a vacuum desiccator overnight. Yield: 4.12 g, 91%. 1H-NMR
(DMSO-d6) δ 8.62–8.39 (m, 2H), 8.26 (d, J = 7.2 Hz, 1H), 8.17 (d, J = 7.5 Hz, 1H), 7.95 (t, J = 7.4 Hz, 1H),
6.87 (s, 1H), 4.10 (s, 2H), 3.25 (d, J = 4.1 Hz, 2H), 1.19 (s, 9H). 13C-NMR (DMSO-d6) δ 163.05, 163.00,
155.77, 132.36, 131.38, 131.25, 130.76, 129.71, 128.83, 128.71, 128.39, 122.99, 122.23, 77.46, 37.63, 28.04.
LC-MS (ESI): m/z 319.21 [M ´ Boc + H]+ (100%). Analytical HPLC: 89% purity (254 nm).
3.2.2. tert-Butyl 2-(1,3-dioxo-6-((trimethylsilyl)ethynyl)-1H-benzo[de]-isoquinolin-2(3H)-yl)ethylcarbamate (2)
Compound 1 (4.00 g, 9.54 mmol), TMS acetylene (1.12 g, 1.49 mL, 11.5 mmol), Pd(PPh3)2Cl2
(334 mg, 0.48 mmol), CuI (182 mg, 0.95 mmol) and Et3N (2.90 g, 4.00 mL, 28.6 mmol) were all dissolved
in dry THF (100 mL) and stirred at RT for 2 h under a N2 atmosphere. The solution was combined with
H2O (100 mL) and extracted with dichoromethane (DCM) (3 ˆ 100 mL). The combined extracts were
dried over MgSO4 and evaporated in vacuo to produce a dark brown-black solid, which was subjected
to silica gel chromatography (10% EtOAc in DCM,) to yield the product as a pale yellow solid (Rf = 0.6).
Yield: 1.99 g, 48%. 1H-NMR (DMSO-d6) δ 8.52 (dd, J = 13.6, 7.8 Hz, 2H), 8.39 (d, J = 7.6 Hz, 1H), 7.91
(t, J = 8.0 Hz, 2H), 6.80 (t, J = 6.2 Hz, 1H), 4.13 (t, J = 5.8 Hz, 2H), 3.27 (dd, J = 11.6, 5.9 Hz, 2H), 1.21
(s, 9H), 0.34 (s, 9H). 13C-NMR (DMSO-d6) δ 163.20, 162.91, 155.67, 131.27, 131.01, 130.93, 130.85, 129.53,
127.86, 127.34, 125.68, 122.81, 122.39, 104.51, 101.07, 77.32, 37.63, 27.97, ´0.37. LC-MS (ESI): m/z 337.11
[M ´ Boc + H]+ (100%). Analytical HPLC: 94% purity (254 nm).
3.2.3. 2-(2-Aminoethyl)-6-((trimethylsilyl)ethynyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (3)
Compound 2 (2.00 g, 4.58 mmol) was stirred in a 1:4 (v/v) mixture of DCM and TFA at RT for 4 h.
The DCM and the bulk of the TFA were then removed in vacuo, leaving a thick orange liquid. Upon
the addition of H2O (50 mL), a yellow precipitate formed, which was collected via vacuum filtration,
washed several times with cold H2O and dried in a vacuum desiccator overnight. Yield: 1.48 g, 96%.
1H-NMR (400 MHz, DMSO-d6) δ 8.50 (ddd, J = 8.3, 7.8, 1.0 Hz, 2H), 8.36 (d, J = 7.6 Hz, 1H), 7.95 (dt,
J = 7.4, 4.0 Hz, 2H), 4.30 (t, J = 5.8 Hz, 2H), 3.26–3.06 (m, 2H), 0.36 (s, 9H). 13C-NMR (101 MHz,
DMSO-d6) δ 163.70, 163.41, 131.55, 131.32, 131.13, 130.90, 129.80, 128.34, 127.31, 125.79, 122.78, 122.37,
105.07, 101.16, 37.61, 37.51, ´0.25. LC-MS (ESI): m/z 337.10 [M + H]+. Analytical HPLC: 91% purity
(254 nm).
3.2.4. 2-Bromo-N-(2-(1,3-dioxo-6-((trimethylsilyl)ethynyl)-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl)acetamide (4)
Compound 3 (1.50 g, 4.46 mmol), bromoacetyl bromide (1.80 g, 777 µL, 8.92 mmol) and Na2CO3
(1.42 g, 13.4 mmol) were dissolved in acetone (50 mL) and stirred at RT for 2 h. The solvent was
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removed in vacuo to produce a brown solid. Purification via silica gel chromatography (20% EtOAc in
petroleum spirits) yielded the product as a pale yellow solid (Rf = 0.1). Yield: 1.21 g, 59%. 1H-NMR
(DMSO-d6) δ 8.55–8.46 (m, 2H), 8.36 (dd, J = 7.6, 3.2 Hz, 1H), 7.98–7.91 (m, 2H), 4.13 (t, J = 6.3 Hz, 2H),
3.71 (d, J = 14.0 Hz, 2H), 3.54–3.34 (m, 2H), 0.35 (s, 9H). 13C-NMR (DMSO-d6) δ 131.63, 131.45, 131.23,
130.12, 128.67, 127.62, 125.90, 125.81, 123.20, 123.10, 122.82, 122.70, 105.20, 105.12, 101.53, 61.66, 37.26,
36.67, 29.64, 0.06. LC-MS (ESI): m/z 457.00 (100%) [M + H]+. Analytical HPLC: 97% purity (254 nm).
3.2.5. tri-tert-Butyl 2,21,2”-(10-(2-((2-(1,3-Dioxo-6-((trimethylsilyl)ethyn-yl)-1H-benzo[de]isoquinolin-
2(3H)-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (5)
Compound 4 (350 mg, 0.76 mmol), tBu3DO3A.HBr (414 mg, 0.70 mmol), and DIPEA (180 mg,
242 µL, 1.39 mmol) were dissolved in ACN (50 mL) and the mixture refluxed overnight. The solvent
was removed in vacuo and the residue subjected to silica gel chromatography (5% MeOH in DCM) to
isolate the product as a glassy yellow solid (Rf = 0.1). Yield: 460 mg, 81%. 1H-NMR (CDCl3) δ 8.56 (dd,
J = 8.4, 1.1 Hz, 1H), 8.53 (dd, J = 7.3, 1.1 Hz, 1H), 8.41 (d, J = 7.6 Hz, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.76
(dd, J = 8.3, 7.4 Hz, 1H), 4.37–1.97 (broad set of overlapping signals, 28H), 1.42 (d, J = 2.9 Hz, 27H),
0.33 (s, 9H). 13C-NMR (CDCl3) δ 172.51, 172.19, 164.34, 164.02, 132.61, 131.85, 131.74, 131.18, 130.49,
128.00, 127.61, 127.46, 122.75, 122.16, 105.53, 101.26, 81.86, 81.81, 56.49, 55.76, 54.23, 42.60, 39.61, 38.36,
28.24, 28.06, 27.99, ´0.08. LC-MS (ESI): m/z 446.47 [M + 2H]2+ (100%). Analytical HPLC: 93% purity
(254 nm).
3.2.6. 2,21,2”-(10-(2-((2-(6-Ethynyl-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl)amino)-2-oxoethyl)-1,
4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (L)
Compound 5 (320 mg, 0.36 mmol) and KF (42 mg, 0.72 mmol) were dissolved in 1:1 (v/v) mixture
of H2O and ACN (10 mL) and the solution stirred for 3 h at RT. The solvent was removed in vacuo and
the remaining residue dissolved in a 1:1 (v/v) mixture of TFA and DCM and stirred O/N at RT. After
removal of the TFA and DCM using a nitrogen stream, the crude product was purified by preparative
HPLC. Lypholisation yielded a fluffy orange solid. Yield: 167 mg, 71%. 1H-NMR (CD3OD) δ 8.73 (dd,
J = 8.4, 1.1 Hz, 1H), 8.62 (dd, J = 7.3, 1.1 Hz, 1H), 8.52 (d, J = 7.6 Hz, 1H), 8.00 (d, J = 7.6 Hz, 1H),
7.93 (dd, J = 8.4, 7.4 Hz, 1H), 4.42 (s, 1H), 4.49–3.00 (broad set of overlapping signals, 28H). 13C-NMR
(CD3OD) δ 164.40, 164.08, 132.07, 131.78, 131.39, 130.00, 127.79, 127.69, 126.68, 122.65, 122.31, 118.15,
115.24, 39.21, 37.74. HRMS (ESI): m/z calc’d for [M + H]+, M = C32H38N6O9: 651.2779, found: 651.2773.
Analytical HPLC: 96% purity (254 nm).
3.2.7. Gd-L
Ligand L (38 mg, 47 µmol) and Gd(OAc)3 (39 mg, 120 µmol) were dissolved in MilliQ H2O
(5 mL) and the pH adjusted to ca. 7 with 2 M NaOH. The resulting solution was stirred at 70 ˝C for 2 h,
after which time LC-MS showed complete complexation. The product was purified via preparative
HPLC and isolated as a fluffy orange solid following lyophilisation. Yield: 20 mg, 53%. Anal. Calc’d
for C32H35N6O9Gd¨ 6H2O: C, 42.10; H, 5.19; N, 9.20. Found: C, 42.09; H, 5.06; N, 9.11. HRMS (ESI):
m/z calc’d for [M + H]+, M = C32H35N6O9Gd: 806.1785, found: 806.1779. Analytical HPLC: 96% purity
(254 nm).
3.2.8. “Clicked” Gd-L
Ligand L (38 mg, 47 µmol) and Gd(OAc)3 (39 mg, 120 µmol) were dissolved in MilliQ H2O (5 mL)
and pH adjusted to ca. 7 with 2 M NaOH. The resulting solution was stirred at 70 ˝C for 2 h. After
this time, the pH of the solution was readjusted to ca. 7, then 3-azidopropan-1-ol (9.6 mg, 95 µmol),
sodium ascorbate (18.7 mg, 95 µmol), CuSO4 (0.7 mg, 5 µmol) and THPTA (4.3 mg, 10 µmol) added
and the mixture stirred at RT O/N. The product was purified by preparative HLPC and isolated as a
fluffy orange solid after lyophilisation. Yield: 20 mg, 47%. Anal. Calc’d for C35H42N9O10Gd¨ 6H2O:
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C, 41.45; H, 5.37; N, 12.43. Found: C, 41.82; H, 5.27; N, 12.36. HRMS (ESI): m/z calc’d for [M + H]+ M =
C35H42N9O10Gd: 907.2374, found: 907.2413. Analytical HPLC: 96% purity (254 nm).
3.2.9. Peptide Conjugation
To a solution of Myr-Lys(N3)-YGRKKRRQRRR [55] (10 mg, 5.2 µmol) in MilliQ water (5 mL)
was added Gd-L (10 mg, 12 µmol), followed by CuSO4 (0.8 mg, 5 µmol), THPTA (4.5 mg, 10 µmol)
and sodium ascorbate (3.1 mg, 16 µmol). The pH was then adjusted to 6–7 with 1 M HCl and the
mixture stirred O/N at RT. Peptide LC-MS analysis showed near-complete consumption of starting
peptide after this time. The product was isolated as a white solid following preparative HPLC and
lyophilisation. Peptide LC-MS (ESI): m/z 986.95 [M + 2TFA + H]3+, 90% purity (214 nm).
3.3. Quantum Yield Determinations
Complexes were prepared at a range on concentrations in a 100 mM HEPES buffer at pH 7.4, and
absorbance and fluorescence emission spectra recorded. Quantum yields (Φ) were then determined,
using quinine sulphate in 0.1 M sulfuric acid as the reference compound (Φ = 54%) [80], according to
the following equation:
ΦX “ ΦSTˆpGradx{GradSTqˆ pηX{ηSTq2
where Φ is the quantum yield, X and ST denote the sample and reference, respectively, Grad is the
gradient of the integrated fluorescence vs. absorbance plot, and η represents the refractive index of
the solvent.
3.4. Cell Culture
Tongue squamous carcinoma cells (CAL-33) were cultured in phenol red-free RPMI medium
(Gibco) supplemented with 10% fetal calf serum (FCS, Gibco), 1% glutamax (Gibco), 100 U penicillin mL´1,
100 µg streptomycin mL´1 at 37 ˝C and 6% CO2.
3.5. Cytotoxicity Studies
Cytotoxicity studies of the effect of irradiation on CAL-33 cells treated with Gd-L, “clicked”
Gd-L and the Gd-L-Tat peptide conjugate were performed via a fluorimetric cell viability assay using
resazurin (Promocell GmbH). Briefly, one day before treatment, cells were plated in triplicate into
96-well plates at a density of 4 ˆ 103 cells¨well´1 in 100 µL of medium. After addition of increasing
concentrations of the test compound, cells were incubated for 4 h, then the medium was replaced with
fresh medium devoid of compound. The plates were irradiated for 10 min at 350 nm (2.58 J¨ cm´2) in a
Rayomet Chamber Reactor. Upon further incubation at 37 ˝C in 6% CO2 for 44 h, the medium was
removed and complete medium (100 µL) containing resazurin (0.2 mg¨mL´1 final concentration) was
added. After 4 h of incubation at 37 ˝C in 6% CO2, the fluorescence of the intensely red fluorescent
resorufin product was quantified using a SpectraMax M5 microplate reader (excitation: 540 nm;
emission: 590 nm).
3.6. Cellular Uptake Studies
Cellular uptake and localisation of Gd-L, “clicked” Gd-L and the Gd-L-Tat peptide conjugate was
assessed by confocal fluorescence microscopy. CAL-33 cells were grown on 18-mm Menzel-gläser
coverslips at a density of 2 ˆ 105 cells¨mL´1 and incubated for 4 h with one of the compounds
(100 µM). Cells were fixed in 4% formaldehyde in phosphate-buffered saline (PBS), washed with PBS
and H2O, and mounted on slides for viewing. Fixed cells were viewed on a CLSM Leica SP5 microscope
(Heerbrugg, Switzerland), with the compounds visualised using the hybrid 1 red wavelength selection
on the microscope (excitation: 405 nm; emission: 600´800 nm). It should be noted that there is the
possibility that fixation may change the cellular localisation of fluorescent molecules as they may be
washed out or redistributed.
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4. Conclusions
In conclusion, we have developed a new Gd(III)-DOTA-naphthalimide complex that can be
readily conjugated to azide-bearing molecules via the Cu(I)-catalysed click reaction to introduce a
fluorescent and photo-cytotoxic label. Whilst the photo-physical properties of the naphthalimide
group are not optimal for PDT, the complex represents a useful prototype building block for the facile
construction of new theranostic agents for combined PDT and optical imaging. By virtue of the Gd
centre, the complex could also serve as an effective MRI contrast agent if incorporated into appropriate
in vivo imaging agent designs. Future work will include measurement of the proton nuclear magnetic
relaxation dispersion of the “clicked” Gd-L complex to confirm this capability. Since MRI is a very
insensitive technique, it will also be important to establish conjugate designs that are able to deliver
sufficient concentrations of Gd-L to desired sites (e.g., diseased tissue) to provide adequate image
contrast in vivo.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/21/2/194/s1.
NMR spectra of reported compounds, LC traces for final ligand, Gd(III) complexes and peptide conjugate.
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Abbreviations
The following abbreviations are used in this manuscript:
ACN: acetonitrile
BOC: tert-butoxycarbonyl
tBu3DO3A: tert-butyl-protected 1,4,7,10-tetraazacyclodocane-1,4,7,10-tetraacetic acid
d: doublet
dd: doublet of doublets
ddd: doublet of doublet of doublets
dt: doublet of triplets
DCM: dichloromethane
DIC: differential interference contrast
DIPEA: N,N-diisopropylethylamine
DMF: N,N-dimethylformamide
DOTA: 1,4,7,10-tetraazacyclodocane-1,4,7,10-tetraacetic acid
ESI: electrospray ionization
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HPLC: high-performance liquid chromatography
HRMS: high-resolution mass spectrometry
IC50: half maximal inhibitory concentration
J: coupling constant
LC-MS: liquid chromatography-mass spectrometry
m: multiplet
MRI: magnetic resonance imaging
NMR: nuclear magnetic resonance NMR
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O/N: overnight
PBS: phosphate-buffered saline
PDT: photo-dynamic therapy
PI: photo-toxic index
RT: room temperature
Rf: retention factor
s: singlet
SPAAC: strain-promoted azide-alkyne cycloaddition
t: triplet
TAT: trans-activator of transcription
THF: tetrahydrofuran
TFA: trifluoroacetic acid
THPTA: tris(3-hydroxypropyl-triazolylmethyl)amine
TLC: thin layer chromatography
TMS: trimethylsilyl
UV-A: ultraviolet A radiation
Φ: quantum yield
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